List of Excipients in Branded Drug COLESTID

Company	Tradename	Ingredient	NDC	Excipient	Potential Generic Entry
Pharmacia & Upjohn Company LLC	COLESTID	colestipol hydrochloride	0009-0260	SILICON DIOXIDE
Pharmacia & Upjohn Company LLC	COLESTID	colestipol hydrochloride	0009-0450	CARNAUBA WAX
Pharmacia & Upjohn Company LLC	COLESTID	colestipol hydrochloride	0009-0450	HYPROMELLOSE
Pharmacia & Upjohn Company LLC	COLESTID	colestipol hydrochloride	0009-0450	MAGNESIUM STEARATE
Pharmacia & Upjohn Company LLC	COLESTID	colestipol hydrochloride	0009-0450	POVIDONE
Pharmacia & Upjohn Company LLC	COLESTID	colestipol hydrochloride	0009-0450	SILICON DIOXIDE
Pharmacia & Upjohn Company LLC	COLESTID	colestipol hydrochloride	0009-0450	TRIACETIN

COLESTID Excipient Strategy and Commercial Opportunities

Last updated: September 24, 2026

Colestid contains colestipol hydrochloride, a nonabsorbed bile acid sequestrant used to reduce LDL cholesterol. Its commercial opportunity is primarily a formulation and lifecycle-management opportunity, not a new-molecule exclusivity opportunity. The strongest product concepts address dose bulk, poor palatability, gastrointestinal tolerability, dispersion, adherence, and compatibility with concomitant medicines.

Colestipol is a high-dose, polymeric active pharmaceutical ingredient. The drug is administered as 5-g tablets or oral granules, with maintenance dosing commonly ranging from 5 to 30 g daily depending on the product and clinical response. The excipient system must support swallowability, rapid wetting, uniform dispersion, acceptable mouthfeel, low dust, and minimal binding of other oral medicines.[1]

What is Colestid and how is it formulated?

Colestid is the branded product name for colestipol hydrochloride. It is supplied in tablet and oral granule dosage forms. Colestipol is not systemically absorbed under normal conditions. It binds bile acids in the gastrointestinal tract, preventing their reabsorption and increasing hepatic conversion of cholesterol into bile acids.[1]

Attribute	Colestid profile
Active ingredient	Colestipol hydrochloride
Drug class	Bile acid sequestrant
Route	Oral
Dosage forms	Tablets and oral granules
Typical dose burden	High, commonly grams per day
Systemic absorption	Essentially nonabsorbed
Primary formulation risks	Bulk, palatability, dispersion, constipation, drug binding
Principal regulatory pathway for follow-on product	ANDA, subject to product-specific requirements
Primary commercial differentiator	Administration experience and adherence

The product’s nonabsorbed mechanism reduces systemic exposure concerns but does not eliminate formulation complexity. Colestipol can interfere with absorption of other oral medicines. Product labeling generally recommends administering other drugs at least one hour before or four hours after colestipol.[1]

What excipients are most important for Colestid products?

The highest-value excipient functions are dispersibility, taste and odor masking, texture control, lubrication, tablet mechanical strength, and gastrointestinal tolerability.

Tablets

Tablet excipients must permit compression of a large dose without producing excessively large or friable tablets. Relevant excipient classes include:

Excipient function	Candidate classes	Commercial purpose
Diluent and compressibility aid	Microcrystalline cellulose, dibasic calcium phosphate, mannitol	Controls tablet size and hardness
Binder	Povidone, copovidone, hydroxypropyl cellulose	Improves granule and tablet integrity
Disintegrant	Crospovidone, croscarmellose sodium, sodium starch glycolate	Supports breakup after ingestion
Glidant	Colloidal silicon dioxide	Improves powder flow
Lubricant	Magnesium stearate, sodium stearyl fumarate	Reduces ejection force
Coating or moisture barrier	Hypromellose, polyvinyl alcohol, lipid-based coating systems	Improves handling and swallowability
Taste and mouthfeel modifier	Polyols, film coatings, lipidic excipients	Reduces chalkiness and unpleasant mouthfeel

The main tablet constraint is dose-to-volume ratio. A formulation that reduces excipient mass but creates a hard, slow-dispersing tablet may worsen adherence. Conversely, a highly porous tablet may increase friability, dusting, or moisture sensitivity.

A practical development target is a smaller, smooth, film-coated tablet with adequate mechanical strength and rapid gastrointestinal dispersion. The product should not rely on an enteric coating because colestipol acts locally in the intestinal lumen and delayed release could create an unnecessary performance risk.

Oral granules

Granules offer greater flexibility than tablets because they can be dispersed in water or a beverage before administration. The principal excipient requirements are:

• Rapid wetting and sedimentation control.
• Low dust generation.
• Uniform dosing from a sachet or bottle.
• Flavor masking without excessive sweetness.
• Suspension stability during the short administration period.
• Low foaming.
• Minimal grittiness.
• Compatibility with acidic and neutral beverages.

Candidate excipient systems include sucrose or polyol carriers, maltodextrin, hydrocolloids, wetting agents, flavor systems, acidulants, and anti-caking agents. The formulation should avoid excessive viscosity because patients may perceive a thick suspension as difficult to consume. High viscosity can also cause dose retention on the container wall.

Suspension and stick-pack systems

A single-dose stick pack containing premeasured granules is commercially attractive because it reduces measuring errors and improves portability. A unit-dose product can be positioned for patients who take multiple chronic medicines and need predictable timing around colestipol administration.

Potential product formats include:

1. Flavored granules for dispersion in water.
2. Granules intended for mixing with a soft food vehicle.
3. Low-dust powder in a tear-open sachet.
4. A ready-to-mix suspension with short in-use stability.
5. A dispersible tablet designed to reduce swallowing difficulty.

Each format introduces a different regulatory and technical burden. A ready-to-use liquid would face greater preservative, microbial, packaging, viscosity, and stability requirements than a dry granule product.

What formulation problems create the largest commercial opportunity?

The largest opportunity is improving administration rather than changing the pharmacology.

Palatability and mouthfeel

Bile acid sequestrants have a long history of adherence problems. Colestipol granules can be perceived as gritty, bulky, or difficult to suspend. Flavor systems should be screened against:

• Resin-associated taste and odor.
• Bitterness from the active or excipients.
• Persistence in the mouth.
• Interaction with acidic beverages.
• Sweetener aftertaste.
• Patient preference among adult populations.

A citrus or berry profile may improve acceptability, but flavor selection must account for the product’s intended mixing vehicle. A flavor that performs well in water may perform poorly in milk, juice, or soft food.

Taste masking can use a combination of flavor, sweetener, particulate coating, and mouthfeel modification. Complete encapsulation of the resin may be counterproductive if it reduces wetting or slows access to the intestinal lumen.

Dose burden

Colestipol is administered in gram quantities. A lower-mass product is difficult to achieve through excipient selection alone because the active polymer itself determines much of the dose volume. The most realistic strategies are:

• Higher-density granules.
• More efficient tablet compression.
• Reduced interparticle void volume.
• Unit-dose packaging that makes the dose appear manageable.
• Split dosing with a clear administration schedule.
• Combination or co-packaging with adherence aids.

A claim that a new formulation substantially reduces dose burden would require careful comparative testing. The active amount cannot be reduced without demonstrating equivalent bile acid binding and LDL-lowering performance.

Gastrointestinal tolerability

Constipation, abdominal discomfort, nausea, and bloating are clinically relevant barriers. Excipients cannot eliminate adverse effects caused by the resin, but a formulation can reduce avoidable contributors such as poor dispersion, clumping, and inadequate fluid administration.

The most defensible strategy is to improve dispersion and provide explicit fluid-use instructions. Aggressive use of osmotic excipients or laxative excipients could create new tolerability problems and complicate labeling.

Concomitant drug binding

Colestipol can reduce absorption of other oral drugs. Excipients that alter wetting, swelling, residence time, or dispersion could affect the extent of drug binding. Development should therefore include in vitro binding screens with representative concomitant medicines, including:

• Thyroid hormones.
• Warfarin and other narrow-therapeutic-index drugs.
• Digoxin.
• Thiazide diuretics.
• Oral contraceptives.
• Fat-soluble vitamins.
• Certain antibiotics.

A product designed for rapid dispersion may improve dose uniformity but could increase the rate at which the resin contacts co-administered medicines. The commercial label and dosing window must remain clear.

What patents protect Colestid and its formulation opportunities?

The original composition-of-matter and product protection for colestipol are long expired. Colestid does not present the type of active-molecule patent barrier associated with recently approved small-molecule drugs. A new entrant would focus on formulation, manufacturing, packaging, delivery, or use patents.

IP category	Relevance to colestipol
Original active-ingredient patents	Expired
Original Colestid product patents	Expected to be expired or commercially inactive
Orange Book patent protection	No meaningful current brand exclusivity should be assumed without a live FDA listing review
Formulation patents	Potentially available for granule structure, coating, taste masking, or dispersibility
Manufacturing patents	Potentially available for resin cross-linking, particle-size control, granulation, and drying
Packaging patents	Potentially available for low-dust unit-dose delivery
Method-of-use patents	Possible for patient subgroups or dosing regimens, but likely narrow
Trade secrets	Important for resin particle engineering, flavor systems, and process controls

A follow-on developer should not rely on broad claims directed to “colestipol plus excipients.” Such claims may face enablement, written-description, obviousness, or lack-of-novelty challenges. Stronger claims would tie the excipient system to measurable performance, such as:

• A defined particle-size distribution.
• A specified dispersion time.
• Reduced sedimentation or agglomeration.
• A controlled moisture range.
• A low-dust granule profile.
• A defined flavor-masking architecture.
• A particular manufacturing sequence.
• Improved dose uniformity after suspension.

The most defensible patent estate would combine composition claims with process and performance claims.

When does Colestid lose exclusivity?

Colestid’s core exclusivity has already expired. Colestipol is an established generic active ingredient, and the principal barrier to entry is product execution rather than branded exclusivity.

FDA regulatory status

Colestid is an FDA-approved prescription product historically marketed as tablets and granules. Generic colestipol products may be approved through the ANDA pathway if they meet applicable requirements for active ingredient, strength, dosage form, route, labeling, and bioequivalence or product-specific equivalence standards.[2]

For a new excipient-driven version, the pathway depends on how closely the product matches an existing reference product:

• An ANDA may be appropriate for a therapeutically equivalent tablet or granule.
• A 505(b)(2) application may be more appropriate for a materially different dosage form, administration method, or formulation requiring new clinical or pharmacology data.
• A new flavor, package, or manufacturing process may remain within an ANDA strategy if the product meets FDA requirements and does not create a clinically meaningful difference.
• A liquid or novel delivery system may require additional bridging work.

Orange Book status

The FDA Orange Book is the controlling source for current patent and exclusivity listings. Colestid’s commercial strategy should assume that any current value lies in product differentiation, manufacturing reliability, and distribution rather than in unexpired original patents.[2]

A launch plan must verify:

• Current reference-listed drug status.
• Active approved strengths and dosage forms.
• Therapeutic-equivalence ratings.
• Discontinued-product status.
• Any listed patents or exclusivity codes.
• Whether the intended product is eligible for ANDA referencing.

How many patents cover Colestid today?

No meaningful commercial conclusion should be based on a raw patent count. The relevant question is whether enforceable claims cover the proposed excipient architecture, process, or delivery format.

A practical freedom-to-operate review should cover:

1. Colestipol hydrochloride compositions.
2. Cross-linked or modified polystyrene-divinylbenzene resins.
3. Particle-size and porosity control.
4. Granulation and drying processes.
5. Taste-masked ion-exchange resins.
6. Low-dust powder systems.
7. Sachet and stick-pack delivery.
8. Suspension and reconstitution systems.
9. LDL-lowering methods using modified dosing schedules.
10. Manufacturing equipment and in-process controls.

The search should include U.S., European, Canadian, Japanese, Chinese, and major Latin American filings. Patent families directed to general ion-exchange resins may be more relevant than documents naming Colestid directly.

Which commercial opportunities exist for Colestid excipients?

1. Premium generic granules

A flavored, low-dust, unit-dose granule product is the clearest opportunity. It can compete on adherence and convenience while preserving the established pharmacology.

Commercial advantages include:

• Lower measuring burden.
• Improved portability.
• Better dose consistency.
• Reduced powder handling.
• Potential pharmacy substitution if regulatory requirements are met.

2. Smaller or easier-to-swallow tablets

A tablet redesign could target patients who reject granules or have difficulty swallowing large tablets. The product must balance compression, disintegration, and tablet size. A multiparticulate tablet or coated mini-tablet system could provide a differentiated platform, but it would require careful equivalence testing.

3. Hospital and institutional packaging

Hospitals, long-term-care facilities, and specialty pharmacies may value unit-dose packaging, clear separation from other medicines, and reduced preparation time. Packaging that visibly communicates the required administration interval could reduce medication-timing errors.

4. Pediatric or dysphagia-focused products

A soft-food-compatible granule system may address patients who cannot swallow tablets. Pediatric positioning would require age-appropriate palatability, dosing flexibility, and clinical support. This is a higher-regulatory-risk opportunity because dosing and administration instructions would need to be supported for the proposed population.

5. Combination adherence programs

Colestipol can be positioned for patients who cannot tolerate or do not respond adequately to statins, although it is not a direct pharmacologic substitute for modern LDL-lowering agents. Commercial programs could combine packaging, medication-timing tools, and counseling with a differentiated generic product.

How does Colestid compare with competing lipid-lowering drugs?

Colestipol competes against statins, ezetimibe, PCSK9 inhibitors, bempedoic acid, and other lipid-lowering therapies. Its advantages are nonabsorption and a long-established safety profile. Its disadvantages are dose bulk, gastrointestinal effects, administration complexity, and interaction with other oral drugs.

Product class	Main advantage	Main weakness versus colestipol	Excipient opportunity
Statins	Low dose, inexpensive, strong efficacy	Intolerance in some patients	Limited need for adherence-driven reformulation
Ezetimibe	Small tablet, convenient dosing	Systemic exposure	Combination and packaging opportunities
PCSK9 inhibitors	High LDL reduction	Injectable, higher cost	Device and biologic formulation focus
Bempedoic acid	Oral nonstatin option	Systemic adverse-effect considerations	Tablet lifecycle management
Colestipol	Nonabsorbed mechanism, established use	High dose and poor palatability	Strongest opportunity for excipient innovation

Colestipol is unlikely to win a broad efficacy comparison against high-intensity statins or PCSK9 inhibitors. Its opportunity is narrower: patients requiring a nonabsorbed agent, patients with intolerance to other therapies, and price-sensitive markets where a differentiated generic can improve adherence.

What generic launch risks exist?

The principal launch risks are regulatory equivalence, weak patient acceptance, and limited reimbursement differentiation.

Risk	Business impact	Mitigation
Product not therapeutically equivalent	Delayed or rejected ANDA	Early comparative product and performance testing
Poor suspension behavior	Low adherence and complaints	Optimize wetting, sedimentation, and redispersibility
Flavor failure	Low repeat use	Screen multiple flavors with target patients
Excessive tablet size	Limited adoption	Evaluate granules, mini-tablets, or multiparticulates
Drug-binding interactions	Labeling and safety concerns	Conduct in vitro and clinical interaction studies where needed
Manufacturing variability	Batch failures	Control particle size, moisture, density, and flow
Limited payer premium	Weak return on formulation investment	Target unit-dose, institutional, or specialty channels
Patent challenge	Litigation cost	Build a narrow, evidence-based formulation estate

What licensing deals are realistic for Colestid formulation technology?

Licensing opportunities are more likely to involve excipient platforms, resin engineering, flavor masking, granulation, or packaging than the Colestid brand itself.

Potential transaction structures include:

• An exclusive license for a taste-masked colestipol granule platform.
• A regional license for a unit-dose sachet product.
• A contract development and manufacturing agreement with a specialty generic company.
• A co-development arrangement with an excipient supplier.
• A royalty-bearing license covering a patented particle-engineering process.
• A supply agreement for a proprietary low-dust granule intermediate.

The most valuable asset would combine patent coverage with demonstrated performance against a marketed reference product. A formulation patent without reproducible manufacturing data is unlikely to command a strong license.

What revenue exposure and market size should investors consider?

Revenue exposure is likely modest relative to newer lipid-lowering products. Colestipol is a mature generic market with price pressure and limited brand power. The commercial upside depends on whether a new product can create a reimbursable differentiation.

A realistic revenue model should separate:

• Base generic substitution revenue.
• Premium revenue from improved granules or packaging.
• Institutional sales.
• Specialty-pharmacy distribution.
• International markets with limited access to newer lipid-lowering therapies.
• Co-branded adherence or disease-management programs.

The largest risk is that payers treat the product as interchangeable with low-cost generic colestipol. In that setting, formulation investment must be justified by higher volume, lower manufacturing cost, or channel-specific demand.

Key Takeaways

• Colestid contains colestipol hydrochloride, a nonabsorbed bile acid sequestrant.
• Original molecule and brand exclusivity are no longer the commercial foundation.
• The strongest opportunity is an improved oral granule or unit-dose sachet.
• Excipient priorities are palatability, dispersion, low dust, dose uniformity, and gastrointestinal tolerability.
• Tablet redesign is possible but constrained by the high active dose and resulting tablet size.
• A new formulation may use an ANDA pathway if it remains sufficiently equivalent to the reference product; materially different delivery systems may require a 505(b)(2) strategy.
• Formulation, manufacturing, packaging, and performance-based patents are more relevant than original composition-of-matter patents.
• Competitive differentiation must focus on adherence and administration rather than superior LDL-lowering efficacy.
• Commercial returns are likely to depend on manufacturing economics, payer treatment, and access to specialty or institutional channels.

FAQs

Can Colestipol be reformulated as a liquid?

Yes, but a liquid product would create additional preservative, microbial, viscosity, packaging, stability, and dose-uniformity requirements. A dry granule sachet is generally a lower-risk commercial option.

Which excipient is best for masking Colestipol taste?

No single excipient is likely to solve the problem. A combination of flavor, sweetener, wetting control, particle coating, and mouthfeel modification is more practical than relying on one taste-masking agent.

Is a Colestid generic protected by a current patent?

The original Colestid and colestipol protections are not expected to provide meaningful current exclusivity. Any live risk would more likely arise from later formulation, process, packaging, or use patents.

Can Colestipol granules be mixed with food?

Product-specific labeling controls the permitted mixing vehicles and administration instructions. A new formulation should validate the intended food or beverage vehicle for dose recovery, dispersion, stability, and palatability.

Does a new Colestipol excipient system require clinical trials?

Not always. An equivalent generic product may rely primarily on pharmaceutical equivalence and applicable FDA equivalence requirements. A materially different dosage form, administration method, or clinical claim may require additional clinical or pharmacology evidence.

References

1. Pfizer Laboratories. (2013). Colestid (colestipol hydrochloride) tablets and granules prescribing information. Pfizer.

2. U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations: The Orange Book. FDA.

3. U.S. Food and Drug Administration. (2013). Guidance for industry: ANDAs for certain highly purified synthetic peptides. FDA.

4. U.S. Food and Drug Administration. (2022). Inactive ingredient database. FDA.

5. U.S. National Library of Medicine. (2024). DailyMed: Colestipol hydrochloride drug labeling. National Library of Medicine.